C5938
Complement factor I from human plasma
>90% (SDS-PAGE)
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
CAS Number:
MDL number:
UNSPSC Code:
12352204
NACRES:
NA.54
Recommended Products
Application
Complement factor I from human plasma has been used in a case study of glucose-starved Staphylococcus aureus. Complement factor I from human plasma has also been used to study the human complement cascade of proteolysis as a target of laser irradiation.
Biochem/physiol Actions
Protease which cleaves and inactivates C3b and C4b
Physical form
Supplied as a 1mg/ml solution in PBS, pH 7.2
Other Notes
View more information on the complement pathway at www.sigma-aldrich.com/enzymeexplorer
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Storage Class Code
10 - Combustible liquids
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Sara C Nilsson et al.
Molecular immunology, 48(14), 1611-1620 (2011-05-03)
Factor I (FI) is a crucial inhibitor controlling all complement pathways due to its ability to degrade activated complement proteins C3b and C4b in the presence of cofactors such as factor H, C4b-binding protein, complement receptor 1 or CD46. Complete
The study of the human complement cascade of proteolysis as a target of laser irradiation
Galebskaia, L., et al.
Biomeditsinskaia Khimiia, 55, 68-72 (2012)
Andrew S Bomback et al.
Clinical journal of the American Society of Nephrology : CJASN, 7(5), 748-756 (2012-03-10)
The principle defect in dense deposit disease and C3 glomerulonephritis is hyperactivity of the alternative complement pathway. Eculizumab, a monoclonal antibody that binds to C5 to prevent formation of the membrane attack complex, may prove beneficial. In this open-label, proof
Stephan Michalik et al.
Molecular & cellular proteomics : MCP, 11(9), 558-570 (2012-05-05)
The cellular amount of proteins not only depends on synthesis but also on degradation. Here, we expand the understanding of differential protein levels by complementing synthesis data with a proteome-wide, mass spectrometry-based stable isotope labeling with amino acids in cell
Factor H-related protein 4 activates complement by serving as a platform for the assembly of an alternative pathway C3 convertase via its interaction with C3b
Hebecker, M. and M. Jozsi
The Journal of Biological Chemistry, 287(23), 19258-19236 (2012)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service